{"id":51131,"date":"2026-03-16T08:43:00","date_gmt":"2026-03-16T01:43:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=51131"},"modified":"2026-03-17T17:49:45","modified_gmt":"2026-03-17T10:49:45","slug":"trial-to-test-mild-hyperbaric-oxygen-therapy-during-active-treatment-for-aggressive-brain-cancer","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=51131","title":{"rendered":"Trial to test mild hyperbaric oxygen therapy during active treatment for aggressive brain cancer"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

LISMORE, Australia<\/span><\/span>, March 16, 2026<\/span><\/span> \/PRNewswire\/ — Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment for high-grade glioma, one of the most aggressive forms of brain cancer.<\/p>\n

\n<\/div>\n

Backed by a $1 million<\/span> philanthropic gift from an anonymous donor, the collaborative research will examine whether delivering oxygen in a pressurised environment during active cancer treatment can improve treatment effectiveness, patient wellbeing, treatment tolerance and recovery.<\/p>\n

The trial is the first of its kind in Australia<\/span> and is also believed to be the first globally to investigate mild hyperbaric oxygen therapy (1.35 ATA, which is a substantially lower pressure than conventional hospital hyperbaric treatment) combined with molecular hydrogen in an oncology setting.<\/p>\n

Hyperbaric oxygen therapy involves breathing concentrated oxygen inside a pressurised chamber, allowing oxygen to dissolve more readily into the bloodstream and reach tissues that are typically oxygen-deprived.<\/p>\n

Solid tumours, including aggressive brain cancers, are often hypoxic (low oxygen). This low-oxygen environment can make cancer cells more resistant to radiotherapy, impair normal tissue healing, and contribute to more aggressive tumour behaviour.<\/p>\n

Because radiotherapy partly relies on oxygen-dependent mechanisms to damage cancer cells, researchers have long hypothesised that improving tissue oxygenation could enhance treatment effectiveness while reducing side effects.<\/p>\n

HBOT is already used in Australian hospitals to treat radiation injuries such as osteoradionecrosis (radiation-damaged bone) and soft-tissue radionecrosis \u2013 the death of healthy tissue caused by high-dose radiation therapy. However, its use during active cancer treatment remains limited and is not part of routine oncology care.<\/p>\n

This study shifts the focus from rehabilitation after treatment to potential supportive use during treatment, addressing a significant evidence gap.<\/p>\n

While previous oncology studies have used high-pressure medical HBOT (2\u20133 ATA), this trial will investigate mild hyperbaric therapy, which operates at lower pressure and may carry a different safety and tolerability profile.<\/p>\n

Mild HBOT has previously shown beneficial outcomes in non-oncology settings, including poor circulation, sports tissue injuries, post-concussion syndromes and Parkinson’s disease.<\/p>\n

Professor Jon Wardle<\/span>, Foundation Director of the National Centre for Naturopathic Medicine (NCNM) at Southern Cross University, said the study represents a significant step forward for evidence-informed integrative oncology.<\/p>\n

“As interest in therapies such as hyperbaric oxygen continues to grow, it is essential that we generate high-quality evidence to inform clinical decision-making,” he said.<\/p>\n

“Partnering with MIOG allows us to investigate HBOT in a real-world clinical environment while maintaining strong academic and research standards.”<\/p>\n

A broadcast-ready media kit, including high-resolution imagery and b-roll of the hyperbaric oxygen chamber, is available here:\u00a0https:\/\/we.tl\/t-EWFFmcwvIM<\/a>\u00a0\u00a0<\/p>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

LISMORE, Australia<\/span><\/span>, March 16, 2026<\/span><\/span> \/PRNewswire\/ — Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment for high-grade glioma, one of the most aggressive forms of brain cancer.<\/p>\n

\n<\/div>\n

Backed by a $1 million<\/span> philanthropic gift from an anonymous donor, the collaborative research will examine whether delivering oxygen in a pressurised environment during active cancer treatment can improve treatment effectiveness, patient wellbeing, treatment tolerance and recovery.<\/p>\n

The trial is the first of its kind in Australia<\/span> and is also believed to be the first globally to investigate mild hyperbaric oxygen therapy (1.35 ATA, which is a substantially lower pressure than conventional hospital hyperbaric treatment) combined with molecular hydrogen in an oncology setting.<\/p>\n

Hyperbaric oxygen therapy involves breathing concentrated oxygen inside a pressurised chamber, allowing oxygen to dissolve more readily into the bloodstream and reach tissues that are typically oxygen-deprived.<\/p>\n

Solid tumours, including aggressive brain cancers, are often hypoxic (low oxygen). This low-oxygen environment can make cancer cells more resistant to radiotherapy, impair normal tissue healing, and contribute to more aggressive tumour behaviour.<\/p>\n

Because radiotherapy partly relies on oxygen-dependent mechanisms to damage cancer cells, researchers have long hypothesised that improving tissue oxygenation could enhance treatment effectiveness while reducing side effects.<\/p>\n

HBOT is already used in Australian hospitals to treat radiation injuries such as osteoradionecrosis (radiation-damaged bone) and soft-tissue radionecrosis \u2013 the death of healthy tissue caused by high-dose radiation therapy. However, its use during active cancer treatment remains limited and is not part of routine oncology care.<\/p>\n

This study shifts the focus from rehabilitation after treatment to potential supportive use during treatment, addressing a significant evidence gap.<\/p>\n

While previous oncology studies have used high-pressure medical HBOT (2\u20133 ATA), this trial will investigate mild hyperbaric therapy, which operates at lower pressure and may carry a different safety and tolerability profile.<\/p>\n

Mild HBOT has previously shown beneficial outcomes in non-oncology settings, including poor circulation, sports tissue injuries, post-concussion syndromes and Parkinson’s disease.<\/p>\n

Professor Jon Wardle<\/span>, Foundation Director of the National Centre for Naturopathic Medicine (NCNM) at Southern Cross University, said the study represents a significant step forward for evidence-informed integrative oncology.<\/p>\n

“As interest in therapies such as hyperbaric oxygen continues to grow, it is essential that we generate high-quality evidence to inform clinical decision-making,” he said.<\/p>\n

“Partnering with MIOG allows us to investigate HBOT in a real-world clinical environment while maintaining strong academic and research standards.”<\/p>\n

A broadcast-ready media kit, including high-resolution imagery and b-roll of the hyperbaric oxygen chamber, is available here:\u00a0https:\/\/we.tl\/t-EWFFmcwvIM<\/a>\u00a0\u00a0<\/p>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-51131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/51131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51131"}],"version-history":[{"count":1,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/51131\/revisions"}],"predecessor-version":[{"id":51367,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/51131\/revisions\/51367"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}